Table 2. Baseline Characteristics of Sustained Responders and Nonresponders who underwent Serial QLFT Studies.
| SVR N = 24 | NR N = 68 | Fisher Exact or T-test p-value | |||
|---|---|---|---|---|---|
| Mean or % | ±SD | Mean or % | ±SD | ||
| Demographics | |||||
| Age | 49.4 | 6.0 | 50.1 | 7.0 | 0.65 |
| BMI (kg/m2) | 28.4 | 4.7 | 30.7 | 5.3 | 0.07 |
| Male (%) | 83% | 68% | 0.19 | ||
| African American (%) | 0% | 17.7% | 0.03 | ||
| Disease Severity | |||||
| Cirrhotic (%) | 20.8% | 48.5% | 0.03 | ||
| Esophageal varices (%) | N/A | 35% | N/A | ||
| Splenomegaly (%) | 29% | 50% | 0.15 | ||
| HCV Characteristics | |||||
| Genotype 1 (%) | 75% | 97% | 0.004 | ||
| HCV RNA (log10 IU/ml) | 6.47 | 0.50 | 6.31 | 0.51 | 0.19 |
| Standard Laboratory Tests | |||||
| Hemoglobin (g/dL) | 15.9 | 1.2 | 15.0 | 1.6 | 0.01 |
| WBC (10−3/μL) | 5.9 | 1.9 | 5.4 | 1.9 | 0.27 |
| Platelet Count(10−3/μL) | 177 | 59 | 160 | 71 | 0.31 |
| Bilirubin (mg/dl) | 0.74 | 0.37 | 0.73 | 0.32 | 0.92 |
| Albumin (g/dl) | 3.90 | 0.35 | 3.67 | 0.36 | 0.01 |
| Prothrombin time (INR) | 1.01 | 0.09 | 1.04 | 0.12 | 0.21 |
| Creatinine (mg/dL) | 0.81 | 0.17 | 0.78 | 0.15 | 0.35 |
| Treatment Course | |||||
| > 80% PEG and RBV during the first 20 Weeks (%) | 83% | 54% | 0.01 | ||
Abbreviations: QLFT, quantitative liver function test; PEG/RBV, peginterferon/ribavirin; SVR, sustained virologic responder; NR, nonresponder; SD, standard deviation; BMI, body mass index; WBC, white blood cell count.